Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2577-2587

  Winblad, Bengt ^a   Black, Sandra E ^b   Homma, Akira ^c   Schwam, Elias M ^d   Moline, Margaret ^e   Xu, Yikang ^d   Perdomo, Carlos A ^e   Swartz, Jina ^f   Albert, Kenneth ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^d PFIZER INC   (United States)

^e EISAI INC   (United States)

^f EISAI CO LTD   (Japan)

Author keywords

Alzheimer's disease; Behavior; Clinical trials; Cognition; Donepezil; Function; Severe

Indexed keywords

CHOLINESTERASE; DONEPEZIL;

ACCIDENTAL INJURY; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BEHAVIOR CHANGE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECT SIZE; ENZYME INHIBITION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NOOTROPIC AGENTS; PIPERIDINES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 72549099594     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903236731     Document Type: Article

References (40)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
2. Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med 2002;34:528-535 (Pubitemid 34779108)
3. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001;16:653-666
4. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145 (Pubitemid 28106032)
5. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244 (Pubitemid 29224502)
6. Mohs RC, Doody RS, Morris JC, et al.; "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488
7. Winblad B, Engedal K, Soininen H, et al.; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495
8. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219 (Pubitemid 38971117)
9. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57:2153]. Neurology 2001;57:613-620
10. Winblad B, Kilander L, Eriksson S, et al.; Severe Alzheimer's Disease Study Group. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-1065
11. Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008;25:399-407 (Pubitemid 351630073)
12. Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459-469 (Pubitemid 47450281)
13. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
14. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr 1992;4(Suppl 1):55-69
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association, 1994
16. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944 (Pubitemid 14076461)
17. Panisset M, Roudier M, Saxton J, et al. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-45
18. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S51-6 (Pubitemid 27303110)
19. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44:2315-2321 (Pubitemid 24984772)
20. Olin JT, Schneider LS, Doody RS, et al. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol 1996;9:176-180
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services publication (ADM), 1976
22. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33-9 (Pubitemid 27303108)
23. Galasko DR, Schmitt FA, Jin S, et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease [abstract]. Neurobiol Aging 2000;21(Suppl 1):S168
24. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314 (Pubitemid 24382728)
25. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48(Suppl):9-15 (Pubitemid 17091427)
26. Quinn J, Moore M, Benson DF. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology 2002;58:433-437 (Pubitemid 34150919)
27. Homma A, Nakamura Y, Kobune S, et al. Reliability study on the Japanese version of the Clinician's Interview-Based Impression of Change. Dement Geriatr Cogn Disord 2006;21:97-103 (Pubitemid 43107135)
28. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122
29. Helmer C, Pérès K, Letenneur L, et al. Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord 2006;22:87-94 (Pubitemid 43909834)
30. Livingston, G, Katona C, Francois C, et al. Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer's disease in the U.K. Int Psychogeriatr 2006;18:527-538 (Pubitemid 44128325)
31. Nadkarni N, Black S. Cognitive outcomes. In Rockwood K, Gautheir S, eds. Trial Designs and Outcomes in Dementia Therapeutic Research. Abingdon, UK: Taylor and Francis, 2006:85-112
32. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
33. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004;19:624-633 (Pubitemid 38996839)
34. Galasko D, Schmitt F, Thomas R, et al. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 2005;11:446-453 (Pubitemid 41167182)
35. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006;10:417-429 (Pubitemid 44845354)
36. Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006;77:8-11 (Pubitemid 43022682)
37. Johannsen P, Salmon E, Hampel H et al.; AWARE Study Group. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. CNS Drugs 2006;20:311-325
38. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146 (Pubitemid 29110331)
39. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-249 (Pubitemid 38401128)
40. Burns A, Bernabi R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomized, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39-47